Announcement • Mar 30
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 26
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 21, 2026 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 21, 2026 Reported Earnings • Oct 22
Third quarter 2025 earnings released: CN¥0.011 loss per share (vs CN¥0.053 loss in 3Q 2024) Third quarter 2025 results: CN¥0.011 loss per share (improved from CN¥0.053 loss in 3Q 2024). Revenue: CN¥87.7m (up 47% from 3Q 2024). Net loss: CN¥4.15m (loss narrowed 86% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2025 Results on Oct 21, 2025 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q3, 2025 results on Oct 21, 2025 Announcement • Jun 30
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • Jun 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.5% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). Board Change • May 13
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Yuqi Song was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • May 12
Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 03, 2025 Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 03, 2025, at 14:30 China Standard Time. Location: 4F, No. 12, Jing'er Road, Biological Park, Chengbei District, Xining, Qinghai China Reported Earnings • May 05
First quarter 2025 earnings released: EPS: CN¥0.016 (vs CN¥0.046 loss in 1Q 2024) First quarter 2025 results: EPS: CN¥0.016 (up from CN¥0.046 loss in 1Q 2024). Revenue: CN¥83.6m (down 1.1% from 1Q 2024). Net income: CN¥8.92m (up CN¥35.8m from 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Announcement • Mar 28
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Dec 27
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.053 loss per share (vs CN¥0.034 loss in 3Q 2023) Third quarter 2024 results: CN¥0.053 loss per share (further deteriorated from CN¥0.034 loss in 3Q 2023). Revenue: CN¥59.7m (up 12% from 3Q 2023). Net loss: CN¥30.6m (loss widened 55% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Announcement • Sep 30
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 02
Second quarter 2024 earnings released: CN¥0.056 loss per share (vs CN¥0.037 loss in 2Q 2023) Second quarter 2024 results: CN¥0.056 loss per share (further deteriorated from CN¥0.037 loss in 2Q 2023). Revenue: CN¥53.9m (up 5.5% from 2Q 2023). Net loss: CN¥33.0m (loss widened 51% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. New Risk • Jul 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 33% per year over the past 5 years. Announcement • Jun 28
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2024 Results on Aug 02, 2024 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 02, 2024 Announcement • Jun 02
Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 21, 2024 Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 21, 2024, at 14:00 China Standard Time. Location: 4F, No. 12, Jing'er Road, Biological Park, Chengbei District, Xining, Qinghai China Reported Earnings • May 01
First quarter 2024 earnings released: CN¥0.046 loss per share (vs CN¥0.049 loss in 1Q 2023) First quarter 2024 results: CN¥0.046 loss per share (improved from CN¥0.049 loss in 1Q 2023). Revenue: CN¥84.5m (up 50% from 1Q 2023). Net loss: CN¥26.9m (loss narrowed 6.3% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Apr 20
Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) announces an Equity Buyback for CNY 50 million worth of its shares. Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) announces a share repurchase program. Under the program, the company will repurchase up to CNY 50 million worth of its shares. The shares will be repurchased at no more than CNY 8.19 per share. The purpose of the program is to maintain company's value and shareholders' equity. The repurchased shares will be used for subsequent sales according to regulations. The program will be funded from company's own funds. The plan will be valid for 3 months. Announcement • Mar 30
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024 Announcement • Dec 29
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 24, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.045 loss in 3Q 2022) Third quarter 2023 results: CN¥0.034 loss per share (improved from CN¥0.045 loss in 3Q 2022). Revenue: CN¥53.3m (up 129% from 3Q 2022). Net loss: CN¥19.7m (loss narrowed 25% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Announcement • Sep 30
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 28
Second quarter 2023 earnings released: CN¥0.037 loss per share (vs CN¥0.043 loss in 2Q 2022) Second quarter 2023 results: CN¥0.037 loss per share (improved from CN¥0.043 loss in 2Q 2022). Revenue: CN¥51.1m (up 69% from 2Q 2022). Net loss: CN¥21.9m (loss narrowed 14% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Jun 28
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 28, 2023 Reported Earnings • Apr 30
First quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.04 loss in 1Q 2022) First quarter 2023 results: CN¥0.049 loss per share (further deteriorated from CN¥0.04 loss in 1Q 2022). Revenue: CN¥56.3m (down 25% from 1Q 2022). Net loss: CN¥28.7m (loss widened 22% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Reported Earnings • Oct 28
Third quarter 2022 earnings released: CN¥0.045 loss per share (vs CN¥0.017 loss in 3Q 2021) Third quarter 2022 results: CN¥0.045 loss per share (further deteriorated from CN¥0.017 loss in 3Q 2021). Revenue: CN¥23.3m (down 32% from 3Q 2021). Net loss: CN¥26.5m (loss widened 157% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Reported Earnings • Sep 02
Second quarter 2022 earnings released: CN¥0.043 loss per share (vs CN¥0.07 loss in 2Q 2021) Second quarter 2022 results: CN¥0.043 loss per share (up from CN¥0.07 loss in 2Q 2021). Revenue: CN¥30.2m (up 13% from 2Q 2021). Net loss: CN¥25.4m (loss narrowed 38% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 27
Full year 2021 earnings released: CN¥0.42 loss per share (vs CN¥0.54 loss in FY 2020) Full year 2021 results: CN¥0.42 loss per share (up from CN¥0.54 loss in FY 2020). Revenue: CN¥127.8m (up 2.8% from FY 2020). Net loss: CN¥248.6m (loss narrowed 22% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance. Reported Earnings • Oct 27
Third quarter 2021 earnings released: CN¥0.017 loss per share (vs CN¥0.066 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CN¥34.4m (up 20% from 3Q 2020). Net loss: CN¥10.3m (loss narrowed 74% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 19
Second quarter 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.08 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CN¥26.7m (up 28% from 2Q 2020). Net loss: CN¥40.9m (loss narrowed 12% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance. Reported Earnings • May 02
Full year 2020 earnings released: CN¥0.54 loss per share (vs CN¥0.01 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥124.3m (down 47% from FY 2019). Net loss: CN¥319.5m (down CN¥325.4m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Dec 29
New 90-day high: CN¥7.12 The company is up 29% from its price of CN¥5.50 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Dec 10
New 90-day high: CN¥6.86 The company is up 35% from its price of CN¥5.10 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Is New 90 Day High Low • Nov 20
New 90-day high: CN¥6.24 The company is up 16% from its price of CN¥5.39 on 21 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 9.0% over the same period. Announcement • Nov 10
Hongta Hotland Asset Management Co., Ltd. completed the acquisition of 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) from Tibet Rongen Technology Co., Ltd. Hongta Hotland Asset Management Co., Ltd. signed a share transfer agreement to acquire 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) from Tibet Rongen Technology Co., Ltd. for approximately CNY 170 million on October 26, 2020. Hongta Hotland Asset Management will acquire 33 million shares of Qinghai Spring Medicinal Resources Technology at CNY 5.09 per share. Hongta Hotland Asset shall pay CNY 99 million to the bank account designated by Tibet Rongen Technology as the first transaction installment. Unless otherwise agreed, Hongta Hotland Asset Management shall pay CNY 68.9 million to Tibet Rongen Technology's designated account within 15 working days from the date when the underlying shares are registered under Hongta Hotland Asset Management’s name as the second transaction installment.
Hongta Hotland Asset Management Co., Ltd. completed the acquisition of 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) from Tibet Rongen Technology Co., Ltd. on November 9, 2020. Post completion share capital has not changed. Tibet Rongen Technology Co., Ltd. holds 240 million shares, accounting for 40.91% of Qinghai Spring Medicinal Resources Technology Co., Ltd. Together with its person acting in concert, Xiao Fong, holds 296 million shares, accounting for 50.58% of Qinghai Spring Medicinal Resources Technology Co., Ltd. and Hongta Hotland Asset Management Co., Ltd holds 33 million shares, accounting for 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥69.1m, with losses widening by 185% from the prior year. Total revenue was CN¥127.7m over the last 12 months, down 48% from the prior year. Announcement • Oct 19
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report Q3, 2020 results on Oct 22, 2020 Is New 90 Day High Low • Sep 26
New 90-day low: CN¥4.68 The company is down 1.0% from its price of CN¥4.73 on 24 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Announcement • Jul 18
Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020 Qinghai Spring Medicinal Resources Technology Co., Ltd. announced that they will report first half, 2020 results on Aug 31, 2020 
